Back to results
US 12,398,103 B2Granted
3-diarylmethylenes and uses thereof
AssigneeAtux Iskay LLC
InventorMichael Ohlmeyer
Life of this patent
Estimating the term…
Abstract
3-Diarylmethylenes are disclosed. The compounds activate PP2A, suppress oncogenic kinase signaling, and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.
Claims9
A compound of formula I:
- or a pharmaceutically acceptable salt thereof,
- wherein:
- B is absent or is selected from a direct bond, O, S, —CH2CH2— or —CH═CH—;
- Q is selected from —(CH2)n—, —O—, —S—, or —SO2—NR5;
- n is 0, 1, or 2;
- U is a group selected from:
- X1, X2, X3, and X4 are independently selected in each instance from hydrogen, halogen, nitro, cyano, (C1-C6)alkyl optionally substituted with —OH, (C1-C6) haloalkyl, (C1-C6)haloalkoxy, (C1-C6) haloalkylthio, —NR1R2, —OR1, —C(O)R1, —OC(O)R1, —C(O)NR1R2, —C(O) OR1, —SR1, —SO2R1, or —SO2NR1R2;
- R1 and R2 are independently selected in each instance from hydrogen or (C1-C6)alkyl;
- Z1 and Z2 are independently selected in each instance from hydrogen, halogen, nitro, cyano, azido, (C1-C6)alkyl, (C1-C6) haloalkyl, (C1-C6)haloalkoxy, (C1-C6) haloalkylthio, —NR3R4, —NR3C(O)R4, —NR3C(O) OR5, —OR3, —C(O)R3, —OC(O)R3, —C(O)NR3R4, —C(O) OR3, —SR3, —SO2R3, or —SO2NR3R4;
- R3, R4 and R3 are independently selected from lower alkyl;
- R3 and R4 may be joined to form a ring;
- R5 is selected from optionally substituted lower alkyl, lower cycloalkyl, or acyl.
9 more elements
A compound, selected from:
- or a pharmaceutically acceptable salt thereof.
A compound, selected from:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.